Health & Life (1781) reported revenue of NT$19.5 million for Oct 2026, -42.3% year on year and -29.0% from the previous month. Revenue for Jan–Oct 2026 was NT$290.6 million (-7.7% year on year).
In Oct 2026, it ranked No. 125 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$19.5 million | -42.3% | -29.0% |
| Sep 2026 | NT$27.5 million | +17.2% | -5.5% |
| Aug 2026 | NT$29.1 million | +33.2% | +38.1% |
| Jul 2026 | NT$21.1 million | -52.3% | -38.1% |
| Jun 2026 | NT$34.1 million | +36.0% | -14.8% |
| May 2026 | NT$40.1 million | +89.1% | +80.7% |
| Apr 2026 | NT$22.2 million | -3.2% | -19.3% |
| Mar 2026 | NT$27.5 million | -30.4% | -15.2% |
| Feb 2026 | NT$32.4 million | +7.7% | -12.7% |
| Jan 2026 | NT$37.1 million | -29.4% | -17.0% |
| Dec 2025 | NT$44.7 million | -14.2% | +15.6% |
| Nov 2025 | NT$38.7 million | -19.6% | +14.0% |
| Oct 2025 | NT$33.9 million | -44.3% | +44.4% |
| Sep 2025 | NT$23.5 million | -69.2% | +7.3% |
| Aug 2025 | NT$21.9 million | -74.2% | -50.5% |
| Jul 2025 | NT$44.2 million | -32.9% | +76.2% |
| Jun 2025 | NT$25.1 million | -30.3% | +18.4% |
| May 2025 | NT$21.2 million | -63.2% | -7.5% |
| Apr 2025 | NT$22.9 million | -1.3% | -42.0% |
| Mar 2025 | NT$39.5 million | -15.3% | +31.3% |
| Feb 2025 | NT$30.1 million | +1.2% | -42.7% |
| Jan 2025 | NT$52.5 million | -58.2% | +0.8% |
| Dec 2024 | NT$52.1 million | -5.3% | +8.4% |
| Nov 2024 | NT$48.1 million | +78.8% | -21.0% |
| Oct 2024 | NT$60.9 million | +79.5% | -20.1% |
Jan–Oct 2026 cumulative: NT$290.6 million (-7.7% YoY)
Other Biotech & Medical companies
Compare with peers: Health & Life vs PEC / Health & Life vs Lotus Pharm / Health & Life vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16